Minimally Invasive Radical Hysterectomy Using Endoscopic Stapler in Stage IB2 or IIA1 Cervical Cancer

A regiszterben nem jelölt feltételek

• Inclusion Criteria:
• 2018 FIGO stage IB2 or IIA1 cervical cancer (tumor maximum diameter ≥2 cm and <4 cm)
• Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
• Planned for Type B or C radical hysterectomy
• With adequate bone marrow, renal, and hepatic function
  • WBC >3.0 × 10⁹ cells/L
  • Platelets >100 × 10⁹ cells/L
  • Creatinine <180 μmol/L
  • Bilirubin <1.5 × normal range
  • AST, ALT < 3 × normal range
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Previous history of other invasive malignancies with no evidence of recurrence for at least 5 years
• Signed and approved consent form
• Exclusion Criteria:
• Histological types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
• Tumor size less than 2 cm classified as 2018 FIGO stage IA1, IA2, or IB1 disease
• The following are observed on preoperative CT or MRI
  • Tumor size ≥4 cm
  • Lymph node metastasis (short axis ≥15 mm)
  • Paracervical invasion
  • Bladder or rectal invasion
  • Distant metastasis
• Prior pelvic or abdominal radiotherapy
• Prior neoadjuvant chemotherapy before surgery
• Unsuitable for surgery due to severe systemic disease at the investigator's discretion
• Difficult to consider intraoperative lymphatic mapping due to
  • Allergy to triphenylmethane compounds
  • History of prior retroperitoneal surgery
  • History of prior pelvic radiotherapy
  • Cases where cold knife or loop electrosurgical excision procedure (LEEP) was performed within 4 weeks prior to study participation
  • Allergy to triphenylmethane compounds